Year None202420232022202120202019 Feb 29, 2024 Arcutis to Present at the TD Cowen 44th Annual Health Care Conference Feb 28, 2024 Arcutis Announces Pricing of $150 Million Public Offering Feb 28, 2024 Arcutis Announces Proposed Public Offering Feb 28, 2024 Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Feb 27, 2024 Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Feb 16, 2024 Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results Feb 06, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 31, 2024 Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference Jan 29, 2024 Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 10 - 18 of 21
